Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert I. Haddad, Thomas Gauler, Jérôme Fayette et al.|Oral Oncology|2019Cited by 10
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H. Machiels, Tim Henrik Brümmendorf, Robert I. Haddad et al.|RWTH Publications (RWTH Aachen)|2015Cited by 0